updat model disappoint
result lower pt
mix result surprisingli soft guidanc reduc
revenu ep estim cut reflect price
eros delay expect new gener product launch challeng
anim health segment chca also lower ep estim
yet convinc plan separ
rx pharma busi truli unlock addit valu maintain hold
expect second consecut year rx pharma revenu declin us
consum growth remain challeng discuss call see note
publish earlier today prgo gener busi impact sever product
launch delay time price eros pick select matur product
accordingli manag lower rx pharma gener revenu outlook
mean key busi segment post revenu declin two
consecut year project declin current forecast
return growth next year conting upon get new product launch back
track g-proair scopolamin etc stabil base gener busi
 mid-singl digit declin pet care setback year forecast growth
chca model modest growth resum assum
return histor increas flagship consum busi yet
includ potenti contribut nasonex rx over-the-counter switch point
await updat potenti launch timelin henc without major categori
over-the-counter rx switch horizon continu think growth chca segment
like remain challeng medium term
lower pt base updat forecast deriv new pt
base unchang new ep estim vs
financi restat reflect divestitur tysabri
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
vertic integr global healthcar
compani develop manufactur distribut
over-the-count over-the-counter healthcar product gener
rx pharmaceut compani largest global
manufactur store brand privat label over-the-counter
pharmaceut product infant formula
benefit signific macro trend consum
accept store brand compani also
brand over-the-counter busi europ follow acquisit
omega decid separ divest
spin etc gener busi uncertain
truli unlock valu sharehold
outcom new ceo uwe rohrhoff strateg review
potenti extern pressur sharehold activ
take-over specul
new product launch chc busi rx
success p-iv challeng larg brand rx product
gener price headwind persist base
chca busi return posit growth
driven new product flow nexium
chci margin continu steadili expand
chc segment realiz stronger anticip net
sale growth much larger impact sb over-the-counter
cost save organ restructur
litig win potenti earlier expect
omega return growth faster expect
gener price environ continu impact rx
chci remain drag prgo busi
lower anticip gross margin expans due
unabsorb fix cost
page
pleas see import disclosur inform page report
